AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMUGENE LTD

0.024

+0.000

Volume:8.33M

Turnover:198.17K

Market Cap:179.17M

PE:-1.36

High:0.024

Open:0.024

Low:0.023

Close:0.024

Loading ...

Overview Company News Filings

Imugene Ltd - Oncarlytics Patent Allowance in China

THOMSON REUTERS

Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher

Imugene Therapy Achieves Two Complete Responses in Patients with Blood Cancer, Shares Rise Past 8%

MT Newswires Live

BRIEF-Imugene Receives A$20 Mln For Convertible Notes Issue

Imugene Receives AU$20 Million From First Tranche of AU$46 Million Capital Raise; Shares Down 3%

MT Newswires Live

Imugene Ltd - Imugene Receives a$20 Mln for Convertible Notes Issue

THOMSON REUTERS

Imugene Receives Nearly AU$12 Million R&D Tax Refund

MT Newswires Live

3 ASX All Ords shares leading the charge in 2025

Australian Shares End Week Higher; ASX Looks to Crack Down on Companies' Allegedly Misleading Disclosures

MT Newswires Live

Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

The Market Herald

Guess which ASX small cap stock is jumping on 'significant milestone'

Imugene Says First Australian Patient Dosed in Lymphoma Trial

MT Newswires Live

ASX Preview: Australian Shares to Open Lower Amid Wall Street Losses

MT Newswires Live

ASX Market Open: Ever-extending US loss streak to bleed into red Friday – unless Oz bucks trend again | Jan 3, 2024

The Market Herald

5 worst ASX All Ordinaries shares of 2024

Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue

MT Newswires Live

Imugene Ltd - Issuance of Convertible Notes & Warrants for up to a$46M

THOMSON REUTERS

Imugene - Capital Raised to Be Used to Fund Co's Ongoing Clinical Trial Pipeline Including Azer-Cel, Others

THOMSON REUTERS

Imugene Ltd-Imugene Confirms Pending Receipt of C.$11M R&D Tax Refund

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.024,"timestamp":1745302320000,"preClose":0.024,"halted":0,"volume":8328723,"delay":0,"nameEN":"IMUGENE LTD","floatShares":6268537663,"shares":7465390573,"eps":-0.017588,"marketStatus":"Not Yet Opened","change":0,"latestTime":"04-22 16:12:00 AEST","open":0.024,"high":0.024,"low":0.023,"amount":198173,"amplitude":0.041667,"askPrice":0.024,"askSize":1109892,"bidPrice":0.023,"bidSize":13108193,"shortable":3,"etf":0,"ttmEps":-0.017588,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.024,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.48569253474788593,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":6268537663,"roa":"-42.92%","roe":"-100.19%","lyrEps":-0.021115,"volumeRatio":0.48569253474788593,"shares":7465390573,"dividePrice":0,"high":0.024,"amplitude":0.041667,"preClose":0.024,"low":0.023,"week52Low":0.023,"pbRate":"2.83","psRate":"-97.40","week52High":0.087,"institutionHeld":0,"latestPrice":0.024,"committee":0.843876,"eps":-0.017588,"divideRate":0,"volume":8328723,"delay":0,"ttmEps":-0.017588,"open":0.024,"prevYearClose":0.037,"prevWeekClose":0.024,"prevMonthClose":0.032,"prevQuarterClose":0.032,"fiveDayClose":0.024,"twentyDayClose":0.035,"sixtyDayClose":0.038},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514042775","title":"Imugene Ltd - Oncarlytics Patent Allowance in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042775?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:59","pubTimestamp":1740520782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2511687824","title":"Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2511687824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511687824?lang=en_us&edition=fundamental","pubTime":"2025-02-14 10:02","pubTimestamp":1739498540,"startTime":"0","endTime":"0","summary":"In afternoon trade on Friday, theS&P/ASX 200 Index is on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 8,574.7 points.Four ASX shares that are rising more than most today are listed below. Here's why they are charging higher:. The Temple & Webster share price is up a further 8% to $17.45. Investors have been bidding the furniture and homeware retailer's shares higher this week following the release of its half year results. Temple & Webster reported a 23.6% increase in revenue to $313.7 million and a 118% jump in net profit after tax to $9 million. The company's CEO, Mark Coulter, said: \"Temple & Webster has again delivered a record half, with strong performance against all key metrics, against a challenging macro and consumer backdrop.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/14/why-gqg-imugene-mirvac-and-temple-webster-shares-are-pushing-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TPW.AU","BK7087","MGR.AU","WBS","BK7049","GQG.AU","BK7067","BK7107","BK7508","BK7510","BK7062","IMU.AU","BK4211","XJO.AU"],"gpt_icon":0},{"id":"2511981683","title":"Imugene Therapy Achieves Two Complete Responses in Patients with Blood Cancer, Shares Rise Past 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511981683","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511981683?lang=en_us&edition=fundamental","pubTime":"2025-02-14 09:41","pubTimestamp":1739497315,"startTime":"0","endTime":"0","summary":"Imugene (ASX:IMU) reported two more complete responses in its phase 1b trial of azer-cel cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a Friday Australi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":1},{"id":"2507764495","title":"BRIEF-Imugene Receives A$20 Mln For Convertible Notes Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507764495","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507764495?lang=en_us&edition=fundamental","pubTime":"2025-01-29 09:23","pubTimestamp":1738113794,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Receives A$20 Mln For Convertible Notes IssueJan 29 (Reuters) - Imugene Ltd IMU.AX:IMUGENE RECEIVES A$20 MILLION FOR CONVERTIBLE NOTES ISSUEFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OO1S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2507573925","title":"Imugene Receives AU$20 Million From First Tranche of AU$46 Million Capital Raise; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507573925","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507573925?lang=en_us&edition=fundamental","pubTime":"2025-01-29 08:26","pubTimestamp":1738110396,"startTime":"0","endTime":"0","summary":"Imugene  received AU$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, representing the first tranche of a AU$46 million capital raise, according to a Wednesday filing with the Australian bourse.The convertible notes have a five-year maturity, the filing said.Proceeds will be used to advance the company's immuno-oncology clinical trial pipeline, according to the filing.Imugene's shares fell nearly 3% in morning trade Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2507526285","title":"Imugene Ltd - Imugene Receives a$20 Mln for Convertible Notes Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507526285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507526285?lang=en_us&edition=fundamental","pubTime":"2025-01-29 05:21","pubTimestamp":1738099272,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2502000806","title":"Imugene Receives Nearly AU$12 Million R&D Tax Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2502000806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502000806?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:19","pubTimestamp":1736482763,"startTime":"0","endTime":"0","summary":"Imugene  received a tax refund of AU$11.7 million for the fiscal year ended June 30, 2023, from the Australian federal government's research and development tax incentive scheme, according to a Friday filing with the Australian bourse.The scheme encourages Australian firms to conduct research and development activities by providing a refund for eligible expenditures.Funds from the rebate will be used by the immunotherapy firm to advance the development of products in the pipeline, the filing said.The company's shares fell past 2% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XKO.AU","BK7067","BK7508","IMU.AU","XJO.AU"],"gpt_icon":0},{"id":"2502009293","title":"3 ASX All Ords shares leading the charge in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502009293","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502009293?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:55","pubTimestamp":1736477701,"startTime":"0","endTime":"0","summary":"Although under pressure today, the All Ordinaries Index is up 1.3% so far in 2025, with three ASX All Ords shares racing ahead of those gains. At market close yesterday, these three companies were leading the charge higher in the nascent new year. You'll also notice a decided trend in the sector they operate in. Which soaring ASX All Ords shares are we talking about?) The EBR Systems share price closed out 2024 at $1.025. In Friday afternoon trade, shares are changing hands for $1.40 apiece. That sees this ASX All Ords stock up 36.6% already in the new year. On Monday, the company, which is developing the world's only wireless cardiac pacing device for heart failure , reported that the US Food and Drug Administration  had scheduled the manufacturing Pre-Approval Inspection  to commence on 14 January. \"This significant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-all-ords-shares-leading-the-charge-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PAI.AU","PAI","BK7508","XJO.AU","BK7067","BK7007","XAO.AU","IMU.AU","CYC.AU","XKO.AU","EBR.AU"],"gpt_icon":0},{"id":"2500159085","title":"Australian Shares End Week Higher; ASX Looks to Crack Down on Companies' Allegedly Misleading Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2500159085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500159085?lang=en_us&edition=fundamental","pubTime":"2025-01-03 14:06","pubTimestamp":1735884405,"startTime":"0","endTime":"0","summary":"Australian shares closed the week higher, tracking Asian markets, despite Wall Street's concerns about high interest rates.The S&P/ASX 200 Index rose 0.6% or 49.3 points to close at 8,250.5.Anticipated fewer rate cuts from the US Federal Reserves, coupled with potential inflationary policies from President-elect Trump hit shares while sending bond yields higher and making the dollar stronger, Reuters reported.In company news, the Australian Securities Exchange  is looking to clamp down on listed companies allegedly providing misleading or evasive information in their market disclosures, according to a report by The Australian.Imugene  dosed the first Australian patient for its phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7039","XKO.AU","ASX.AU","XAO.AU","BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2500135962","title":"Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2500135962","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500135962?lang=en_us&edition=fundamental","pubTime":"2025-01-03 09:31","pubTimestamp":1735867866,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is fighting hard to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,232.7 points. Four ASX shares that are rising more than mos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/why-cettire-gold-road-imugene-and-paladin-energy-shares-are-racing-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7083","BK7067","XKO.AU","XAO.AU","XJO.AU","BK1258","BK7508","PDN.AU","BK7021","BK7104","CTT.AU","GOR.AU","00495","IMU.AU","BK7506","BK1229","BK7509","BK7049"],"gpt_icon":0},{"id":"2500115816","title":"First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care","url":"https://stock-news.laohu8.com/highlight/detail?id=2500115816","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500115816?lang=en_us&edition=fundamental","pubTime":"2025-01-03 08:56","pubTimestamp":1735865760,"startTime":"0","endTime":"0","summary":"Imugene Limited  has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week.This dosage marks the start of Imugene’s Phase 1b trials, which are now mainly focusing on one of the most challenging and aggressive forms of non-Hodgkin’s lymphoma.The idea, the biotechnology company has suggested several times through early testing, is that Azer-cel would offer an off-the-shelf alternative to traditional CAR T-cell therapies – most of which still need lengthy manufacturing that needs patients to share cells and can carry long treatment timelines and costs.This spearhead into Aussie testing comes after Imugene collected “promising data” through its U.S.-based trials; three patients in State-side testing had zero signs of the cancer despite relapsing after other, similar treatments.The material provided in this article is for information only and shou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/first-aussie-doses-bring-imugene-major-step-closer-to-quicker-cheaper-non-hodgkins-lymphoma-care-2025-01-03/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["XAO.AU","XJO.AU","BK7508","BK7067","XKO.AU","IMU.AU"],"gpt_icon":0},{"id":"2500180952","title":"Guess which ASX small cap stock is jumping on 'significant milestone'","url":"https://stock-news.laohu8.com/highlight/detail?id=2500180952","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500180952?lang=en_us&edition=fundamental","pubTime":"2025-01-03 08:28","pubTimestamp":1735864080,"startTime":"0","endTime":"0","summary":"Imugene Ltd  shares are ending the week on a positive note. In late morning, trade, the ASX small cap stock is up 5% to 4.1 cents. Why is this ASX small cap stock roaring higher?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/guess-which-asx-small-cap-stock-is-jumping-on-significant-milestone/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4161","CR","XAO.AU","BK7508","XJO.AU","BK7067","XKO.AU","IMU.AU"],"gpt_icon":0},{"id":"2500573186","title":"Imugene Says First Australian Patient Dosed in Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2500573186","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500573186?lang=en_us&edition=fundamental","pubTime":"2025-01-03 07:19","pubTimestamp":1735859972,"startTime":"0","endTime":"0","summary":"Imugene  the first Australian patient has been dosed in the phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney, according to a Friday filing with the Australian bourse.The trial assesses the safety, tolerability, and clinical activity of azer-cel in patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin's lymphoma, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","IMU.AU","BK7508","XJO.AU","XAO.AU","BK7067"],"gpt_icon":0},{"id":"2500918311","title":"ASX Preview: Australian Shares to Open Lower Amid Wall Street Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2500918311","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500918311?lang=en_us&edition=fundamental","pubTime":"2025-01-03 06:40","pubTimestamp":1735857627,"startTime":"0","endTime":"0","summary":"Australian shares are expected to slip into the red at market open Friday as investors follow losses from Wall Street overnight.The Nasdaq and the S&P 500 shed 0.2% each on Thursday, with Tesla driving the losses following a drop in vehicle deliveries for 2024. The Dow Jones Industrial Average was down 0.4%.In macroeconomic news, the commodity price index rose 0.6% month over month in December 2024 in special drawing rights  terms, following a revised 1.3% increase in the prior month, preliminary data from the Reserve Bank of Australia showed Thursday.In corporate news, Imugene  dosed the first Australian patient in the Phase 1b clinical trial of its azer-cel therapy, which is being assessed as a potential treatment for non-Hodgkin's lymphoma.Arcadium Lithium  and Livent entered into a second supplemental indenture on Jan. 1.UBS Securities Australia ceased to be a substantial holder in SG Fleet Group .Australia's benchmark index rose 0.5%, or 42.10 points, Thursday to close at 8,201.20","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTM.AU","XAO.AU","BK7016","BK7508","SGF.AU","BK7067","SDR","SDR.AU","XKO.AU","BK7036","IMU.AU","BK7064","XJO.AU"],"gpt_icon":0},{"id":"2500153490","title":"ASX Market Open: Ever-extending US loss streak to bleed into red Friday – unless Oz bucks trend again | Jan 3, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500153490","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500153490?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:58","pubTimestamp":1735855080,"startTime":"0","endTime":"0","summary":"The ASX 200 is expected to open 0.07% lower at 8,185 points, though after yesterday’s defiant reversal things may change through morning trade.Futures tipping a drop Down Under comes after the S&P 500 and Nasdaq composite both extended their losing streaks to the longest seen in the U.S. since April – much of which seems to be investors taking profits.Impending U.S. economic data on CPI and payrolls may also be playing a role; fourth-quarter reporting will also be starting all across Wall Street from January 13.One docket that has stood out is Imugene Limited , with the HotCopper forum favourite dosing its first Aussie patient as it tests its Azer-Cel technology.The Australian Securities Exchange  has also declared today that it’s taking its crackdowns into hyperdrive as it keeps dealing with executives declaring company moves poorly – more fines will soon follow.That’s Market Open, I’m Isaac McIntyre, stick with us for HotCopper’s Market Close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-2-2025-01-03/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ASX.AU","BK7508","BK7067","BK7039","IMU.AU"],"gpt_icon":0},{"id":"2500520904","title":"5 worst ASX All Ordinaries shares of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500520904","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500520904?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:00","pubTimestamp":1735851600,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ordinaries Index  shares rose by 7.55% and delivered total gross returns, including dividends, of 11.44% last year.That's a pleasing overall market return in anyone's language.But for some stockpickers, it was a hard year.Investors in the following five ASX All Ordinaries shares endured a teeth-gritting 12 months in 2024.5 ASX All Ordinaries shares that plunged in value in 2024. Here are the five ASX All Ordinaries companies whose share prices declined the most in 2024.ASX All Ordinaries lithium share Liontown was the worst performer of the year in terms of price change.Patriot is the second lithium share comprising the five biggest losers of the ASX All Ordinaries in 2024.Investors were dismayed when nothing came of discussions with US lithium giantAlbemarle Corp last year. The companies ceased talks in May after spending nine months assessing partnership opportunities for a downstream lithium hydroxide plant for Patriot's Corvette Lithium Project in Canada.In November, Wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/5-worst-asx-all-ordinaries-shares-of-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4545","BK4585","LU1244550494.USD","LU1974910355.USD","BK7095","PMT.AU","WC8.AU","BK7507","BK4548","LU0823414478.USD","BK7067","IMU.AU","LU1878469433.USD","LU2023250504.SGD","LU1244550577.SGD","BK7506","BK4109","LU2249611893.SGD","ALB","LU1917777945.USD","BK7078","LU1803068623.USD","SGR.AU","LU1720051108.HKD","BK7504","LU2357305700.SGD","LU1861219969.SGD","LU1548497426.USD","BK7508","LU2106854487.HKD","PLS.AU","LU1244550221.USD","LTR.AU","XAO.AU","LU1861214812.USD","LU1720051017.SGD","BK4588"],"gpt_icon":1},{"id":"2493716748","title":"Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2493716748","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493716748?lang=en_us&edition=fundamental","pubTime":"2024-12-24 05:58","pubTimestamp":1734991104,"startTime":"0","endTime":"0","summary":"Imugene  will raise AU$46 million via the issue of notes and warrants to investor CVI Investments, according to a Monday filing with the Australian bourse.The offer comprises AU$20 million in senior unsecured zero-coupon convertible notes maturing in five years and AU$26 million worth of five-year unlisted warrants exercisable at AU$0.0494, the filing said.If the investor decides to convert the bonds into shares, its conversion value will be 25% above the immuno-oncology firm's closing price on Dec. 20, per the filing.Proceeds will be used to advance the company's azer-cel, onCARlytics, and Vaxinia trials, as per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2493850027","title":"Imugene Ltd - Issuance of Convertible Notes & Warrants for up to a$46M","url":"https://stock-news.laohu8.com/highlight/detail?id=2493850027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493850027?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:30","pubTimestamp":1734935401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NL1J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2493786883","title":"Imugene - Capital Raised to Be Used to Fund Co's Ongoing Clinical Trial Pipeline Including Azer-Cel, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2493786883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493786883?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:30","pubTimestamp":1734935401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NL1J1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2492574871","title":"Imugene Ltd-Imugene Confirms Pending Receipt of C.$11M R&D Tax Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2492574871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492574871?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:54","pubTimestamp":1734558855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUE7VNFSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[]}}